hGH-CTP: Phase II data
Top-line data from an open-label, dose-ranging, international Phase II trial in 39 patients showed that a single weekly injection of hGH-CTP containing 30%, 40% or 100% of the equivalent cumulative commercial dose that a patient would normally inject each day over the course of 7 days led to average IGF-1 levels that were within the normal therapeutic range, +/- 2 standard deviations from the average IGF-1 levels expected in a normal population, on 100% of the days in which the patients were evaluated. At the narrower range of +/- 1.5 standard deviations from the average normal population IGF-1 levels, weekly 30%, 45% and 100% doses of hGH-CTP led to average IGF-1 levels that were within the normal range on 57%, 100% and 86% of days, respectively, in which they were evaluated. ...